MDL (drug)
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MDL (short for Methoxy Dihydro Lysergol) is a metabolite of the drug nicergoline.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | 10-methoxydihydrolysergol; 10-α-methoxy-9,10-dihydrolysergol |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H22N2O2 |
| Molar mass | 286.375 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is member of the ergoline family and is a dehydrogenated and methoxylated lysergol (a lysergol in which the double bond between carbon atoms 9 and 10 has been hydrogenated and a methoxy group is attached to the 10th carbon atom in the α-configuration).
MDL is formed as a result of the N-demethylation of the metabolite MMDL; the enzyme CYP2D6 plays a key role in this chemical reaction, and its individual functional activity determines the efficiency with which this drug is metabolised in the body.[4]
Pharmacology
Pharmacodynamics
Little is known about the serotonergic activity of MDL; however, there is a study evaluating the antioxidant activity of nicergoline metabolites, in which MDL and MMDL protect tissues from oxidation, prevent a drop in glutathione levels and halt lipid peroxidation.[5] In combination with nicergoline, it stimulates astrocytes, causing them to release protective growth factors (TGF-beta and GDNF); however, the metabolite MMDL did not exhibit this effect.[6] It mildly stimulates the synthesis of noradrenaline in the brain and has a weak (low) affinity for alpha-1-adrenoceptors.[7]